Option Care Health (NASDAQ:OPCH) Issues FY 2025 Earnings Guidance

Option Care Health (NASDAQ:OPCH) updated its FY 2025 earnings guidance on Monday. The company provided earnings per share guidance of 1.590-1.690 for the period, compared to the consensus earnings per share estimate of 1.240. The company issued revenue guidance of $5.2 billion-$5.4 billion, compared to the consensus revenue estimate of $5.2 billion. Option Care Health also updated its FY 2024 guidance to 1.550-1.590 EPS.

Option Care Health Price Performance

NASDAQ OPCH opened at $28.72 on Wednesday. The stock has a market cap of $4.89 billion, a price-to-earnings ratio of 24.13, a PEG ratio of 2.43 and a beta of 1.31. Option Care Health has a 12 month low of $21.39 and a 12 month high of $34.63. The company’s 50 day moving average is $23.33 and its two-hundred day moving average is $27.70. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Barrington Research increased their price target on Option Care Health from $32.00 to $33.00 and gave the stock an “outperform” rating in a research note on Tuesday. UBS Group began coverage on Option Care Health in a research report on Thursday, December 5th. They set a “neutral” rating and a $26.00 target price for the company. The Goldman Sachs Group downgraded Option Care Health from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $38.00 to $27.00 in a research note on Monday, November 4th. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 price objective (down from $31.00) on shares of Option Care Health in a report on Friday, January 10th. Finally, Bank of America raised shares of Option Care Health from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $26.00 to $33.00 in a report on Monday. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Option Care Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.86.

Insider Activity

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. purchased 43,000 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was purchased at an average price of $22.54 per share, with a total value of $969,220.00. Following the acquisition, the director now owns 326,334 shares in the company, valued at approximately $7,355,568.36. The trade was a 15.18 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.64% of the company’s stock.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.